|
|
Article: Genzyme Has Satisfying Quarter; Cerezyme Gives 'Upside Surprise'.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
Genzyme Corp. reported first-quarter 2004 results that topped Wall Street's consensus, as company officials during a conference call took questions on legal challenges, patent-estate security and dosing of its enzyme-replacement therapy for Pompe disease.
"Almost across the board, they outperformed," said Christopher Raymond, analyst with Robert W. Baird & Co. in Chicago. "It was an upside surprise that Cerezyme continues to do better than people think. We've all been predicting for a couple of quarters that we'd see a down quarter."
It didn't happen. Once again, Genzyme's three product leaders - Cerezyme, Renagel and Fabrazyme ...